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Abstract Exposure to sex steroids increases the risk of breast
cancer but the exact mechanisms are yet to be elucidated.
Events in the microenvironment are important for carcinogen-
esis. Diet containing phytoestrogens can affect the breast mi-
croenvironment and alter the risk of breast cancer. It has pre-
viously been shown that estrogen regulates extracellular levels
of leptin, adiponectin, and VEGF in normal breast tissue
in vivo. Whether these proteins correlate in breast tissue
in vivo or if diet addition of flaxseed, a major source of
phytoestrogens in Western diets, alters adipokine levels in
breast tissue are unknown. We used microdialysis to sample
proteins of normal human breast tissue and abdominal subcu-
taneous fat in situ in 34 pre-and postmenopausal women.
In vitro, co-culture of breast cancer cells and primary human
adipocytes was used. In vivo, in normal breast tissue, a signif-
icant positive correlation between VEGF and leptin was de-
tected. No correlations were found in fat tissue. Co-culture of
adipocytes and breast cancer cells per se increased the secre-
tion of VEGF and leptin and enhanced the effects of estradiol
compared to culture of either cell type alone. In vitro, inhibi-
tion of VEGF diminished the release of leptin while inhibition
of leptin had no influence on VEGF secretion. The levels of
leptin decreased and adiponectin increased after a dietary ad-
dition of 25 g of flaxseed/day for one menstrual cycle. We
conclude that VEGF and leptin correlate significantly in nor-
mal human breast tissue in vivo and that dietary addition of
flaxseed affect adipokine levels in the breast.
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Introduction
The incidence of breast cancer is increasing in the Western
world. In breast cancer prevention studies, anti-estrogen ther-
apies reduced the incidence of breast cancer by approximately
50 %, but these therapies are associated with severe side ef-
fects such as endometrial cancer, osteoporosis, impaired qual-
ity of life, and thromboembolism [1, 2]. Although sex steroids,
including estrogens, have been shown to affect breast cancer
risk by receptor-mediated processes or via receptor indepen-
dent mechanisms such as generation of genotoxic metabolites,
further mechanisms behind sex steroid induced breast cancer
need to be elucidated [3, 4]. As anti-estrogen drugs are asso-
ciated with poor compliance to the therapy, breast cancer pre-
ventive strategies associated with less side-effects, such as diet
modifications need to be developed. The tissue microenviron-
ment is recognized as a critical player in all steps of carcino-
genesis including breast cancer progression [5]. Increased
knowledge of the regulation of the breast tissue microenviron-
ment it is therefore essential for the development of novel
breast cancer prevention interventions.
Adipocytes are one of the most abundant cell types in the
breast microenvironment, which is characterized by the close
interaction between the different cells types in the breast.
Adipocytes actively secrete proteins including adipokines that
play an important role in the cell-cell interactions in the breast
[6]. The adipokine leptin and its receptor may be found in both
normal and malignant mammary tissue [7]. In breast cancer,
leptin has been associated with increased angiogenesis and
vascular endothelial growth factor (VEGF) one of the most
potent stimulators of angiogenesis [8, 9]. Up-regulation of
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intratumoral and/or circulating VEGF has been associated
with poor prognosis in many solid tumors including breast
cancer [10]. Another adipokine, adiponectin, has been shown
to be a key player in several physiological processes and low
levels of circulating adiponectin have been associated with
breast cancer [11–13]. As adiponectin may counteract the ef-
fects of leptin, the ratio of leptin:adiponectin, has been sug-
gested to be an improved indicator of the biological outcome
rather than their individual concentrations [14]. It has previ-
ously been shown that estradiol plays an important role in the
regulation of the extracellular levels of leptin, adiponectin, and
VEGF in normal human breast in vivo [15–20]. How or if
leptin, adiponectin, and/or VEGF correlate or regulate each
other in normal human breast tissue in vivo is to date un-
known. Previous data has suggested that a dietary addition
of 25 g of flaxseed/day to premenopausal women affected
several inflammatory and angiogenesis regulators in the extra-
cellular environment in normal human breast tissue in vivo
[15, 21]. It is not known if flaxseed affects adipokine levels
in the breast. Our aims of this study were to investigate a
possible relationship of the in vivo levels of leptin,
adiponectin, and VEGF in normal human breast tissue in
pre- and postmenopausal women and to explore their recipro-
cal regulation in an in vitro co-culture model. Moreover, we
investigated if a daily addition of flaxseed to the diet for one
month altered the adipokine levels in normal human breast
tissue in premenopausal women.
Materials and Methods
Human Subjects and Experimental Procedure
The regional ethical review board of Linköping approved the
study and all participants gave their informed consent. As it
previously has been shown that several angiogenesis factors
and adipokines are influences by estrogen levels [15, 20–22]
women during various stages of the menstrual cycle as well as
postmenopausal women with low estrogen levels were includ-
ed in order to take the hormonal fluctuations into account. A
total of 34 women were included in the microdialysis investi-
gations in three different cohorts;
1) Thirteen premenopausal healthy volunteers (age 20–
30 years) with a history of regular menstrual cycles (27–
35 days) were investigated with microdialysis both in
breast tissue and abdominal subcutaneous (s.c.) fat.
Nine of them were investigated in both the follicular
and luteal phases of one menstrual cycle whereas four
premenopausal women were investigated in the luteal
phase of one menstrual cycle.
2) Eleven postmenopausal women (age 58–78) that previ-
ously had undergone surgery for early breast cancer were
investigated with microdialysis in their normal unaffected
breast and in abdominal s.c. fat except for two women
where the fat microdialysis catheter was omitted due to
technical issues.
3) For the diet study another 10 premenopausal women were
investigated with microdialysis in normal breast tissue
and abdominal s.c. fat tissue in the luteal phase of a men-
strual cycle before the start of the diet addition with flax-
seed (un-exposed). Thereafter they added 25 g of freshly
ground flaxseed/day to their regular diet and a second
microdialysis investigation took place in the luteal phase
of the next menstrual cycle (exposed). The women were
monitored using luteinizing hormone (LH) in urine sam-
ples. After the LH peak the first microdialysis investiga-
tion was performed within 5–10 days. The next microdi-
alysis investigation was performed at the same day after
the LH-peak as in the first un-exposed cycle i.e. if the first
microdialysis was performed at day 5 after the LH-peak
the next microdialysis investigationwas also performed at
day 5. All women had been off sex steroid containing
medication such as contraceptive pills or hormone re-
placement therapy for more than three months.
Before the microdialysis catheter insertions, 0.5 ml lido-
caine (10 mg/ml) was injected intracutaneously. One microdi-
alysis catheter was placed in the upper lateral quadrant of the
left breast in the premenopausal women or in upper lateral
quadrant of the unaffected breast in the postmenopausal wom-
en as previously described [16, 23–25]. Microdialysis cathe-
ters (CMA 71/Microdialysis AB, Solna, Sweden), with a tu-
bular dialysis membrane (100 kDa cutoff, 20 mm membrane
length), were used. The catheters were connected to a pump
(CMA 107, CMA/Microdialysis AB) and perfused with NaCl
154 mM and hydroxyethyl starch 60 g/l (Voluven®, Fresenius
Kabi, Uppsala, Sweden) at 0.5 μl/min. After a 60 min equil-
ibration period the sample were collected and stored at
−70 °C. All microdialysis values are given as original raw
data.
For the in vitro tissue culture study, abdominal s.c. fat tissue
was obtained during elective surgery. These women were not
included in the microdialysis investigations.
Cell Culture
MCF7 cells (HTB-22; Human breast adenocarcinoma, estro-
gen receptor (ER) and progesterone receptor positive), obtain-
ed from the American type culture collection (ATCC;
Manassas, Va, USA), were maintained in DMEM without
phenol red (Invitrogen, Carlsbad, CA, USA) supplemented
with 10 % fetal bovine serum (FBS) (Invitrogen), 2 mM glu-
tamine (Invitrogen) 50 IU/ml penicillin-G and 50 μg/ml strep-
tomycin (Invitrogen), at 37 °C in a humidified atmosphere of
5 % CO2. Confluent MCF7 cells were trypsinized and seeded
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in 6 wells plates (Falcon 3046), 25,000 cells/cm2, for 24 h at
37°C in a humidified atmosphere of 5 % CO2 before starting
the co-culture.
Isolation of Adipocytes
Collagenase digestion (type 1, Worthington, NJ, USA) in
modified Krebs-Ringer solution (0.13 M NaC1, 5 mM KCl,
2.5 mM CaC12, 1.2 mM MgSO4, 0.5 mM inorganic phos-
phate, 25 mM Hepes, pH 7.4, 1 % bovine serum albumin,
200 nM adenosine, 2 mM glucose), were used to isolate ma-
ture adipocytes at 37 °C.
Hormone Treatments of Co-Cultured Adipocytes
and MCF7 Cells In Vitro
A fixed volume of isolated mature adipocytes, diluted in an
equal volume of modified Krebs-Ringer solution and double
volume of DMEM containing 7 % bovine serum albumin,
200 nM PIA, 250 nM Hepes, were added to pre-seeded
MCF7 cells in 6 well plates. The co-culture or each cell type
alone were cultured in serum-free medium consisting of a 1:1
mixture of nutrient mixture F-12 (GIBCO, Paisley, UK) and
Dulbecco’s modified Eagle’s medium without phenol red
(GIBCO, Paisley, UK) supplemented with transferrin
(10 μg/ml; Sigma), insulin (1 μg/ml; Sigma), and bovine se-
rum albumin (0.2 mg/ml; Sigma) with or without 10−9 M
estradiol, or the combination of 10−9 M estradiol and
10−6 M fulvestrant. Adipocytes from one single volunteer
were used for each experimental set-up and repeated with fat
from another donor. For the inhibition assays co-cultures were
treated with anti-human leptin antibody (Genway, USA), anti-
human VEGF antibody (Calbiochem, USA), or normal IgG
from the same species (R&D system, USA) at 0.1 μg/ml and
1 μg/ml in presence or absence of 10−9 M estradiol. After 48 h
treatment, the condition medium was collected and stored at
−70 °C for subsequent analysis.
Quantification of Leptin, Adiponectin, and VEGF
The human immunoassay kits (R&D systems, Minneapolis,
USA) were used for leptin (intra-assay variation of 3 % and
inter-assay variation of 4 %), adiponectin (intra-assay varia-
tion of 4 % and inter-assay variation of 7 %), and VEGF
(intra-assay variation of 5 % and inter-assay variation of
7 %) detection in culture media and microdialysates.
Control of Efficacy of Treatments
The efficacy of the antibodies was confirmed by measuring the
concentrations of the protein in the co-cultures with andwithout
specific antibodies; leptin levels decreased from 8800 ± 40 pg/
ml with control antibody compared to 12 ± 0.0 pg/ml with anti-
leptin antibody (n = 5) and VEGF levels decreased from
533 ± 16 pg/ml in presence of control antibody compared to
3 ± 0.01 pg/ml with anti-VEGF antibody (n = 5). Fulvestrant is
a registered anti-estrogen drug (Faslodex®) and its effect was
confirmed in our laboratory by measuring proliferation of hor-
mone dependent breast cancer cells using 5-bromo-2′-
deoxyuridine (BrdU) proliferation kit according to the manu-
facturer’s guidelines (BrdU cell proliferation ELISA, Roche,
Mannheim, Germany). Fulvestrant potently reversed the
estradiol-induced proliferation of hormone dependent breast
cancer cells; relative proliferation in control cells 1 ± 0.02, in
E2 exposed cells 4 ± 0.2 and in E2 + fulvestrant exposed cells
0.8 ± 0.02 (n = 8 in each group).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
software 6.0. Pearson’s correlation coefficient, Wilcoxon
signed rank test, or student’s t test were used as appropriate.
Data are expressed as mean ± SEM. A p < 0.05 was consid-
ered as statically significant.
Results
VEGF Correlated significantly to Leptin in Normal
Human Breast Tissue
Microdialysis was performed in nine premenopausal women in
the follicular and luteal phases of one menstrual cycle (18 oc-
casions), in another 14 premenopausal women in one luteal
phase (14 occasions), and in 11 postmenopausal women (11
occasions), which equals 43 occasions. During each occasion
one microdialysis catheter was inserted in normal breast tissue
and another catheter was inserted in abdominal s.c. fat except
for two occasions where the microdialysis of the abdominal s.c.
fat was omitted. Thus, 43 microdialysis investigations were
performed in breast tissue and 41 microdialysis investigations
were performed in abdominal s.c. fat. There were no subse-
quent complications after the microdialysis investigations.
There was a significant positive correlation between extra-
cellular VEGF levels and extracellular leptin levels in breast
tissue, r = 0.6; p < 0.001; n = 43, but not in the abdominal s.c.
fat, Fig. 1a.
No significant correlations were found between VEGF and
adiponectin in either tissue, Fig. 1b. A significant positive
correlation was found between VEGF and leptin:adiponectin
ratio in the breast, r = 0.4; p < 0.01; n = 43, but not in abdom-
inal s.c. fat, Fig. 1c.
Extracellular breast and extracellular fat VEGF correlated
significantly (r = 0.49) as well as extracellular breast and
extracellular leptin levels (r = 0.50). No correlation was found
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between extracellular breast and extracellular fat adiponectin
(r = 0.08).
VEGF Inhibition Decreased Leptin Levels but not Vice
Versa
To be able to explore if the release of leptin was dependent on
VEGF or vice versa, we set up in vitro cell culture experi-
ments. As we also wanted to explore possible effects of estra-
diol we co-cultured freshly isolated human adipocytes with
the ER+ MCF7 breast cancer cells since established normal
human breast epithelial cell lines lack the expression of ER
[26, 27].
In co-cultures, treatment with an anti-VEGF antibody re-
sulted in a dose-dependent inhibition of extracellular leptin
levels whereas inhibition of leptin did not alter the release of
VEGF, Fig. 2.
Next, we investigated if inhibition of the different proteins
with antibody treatments to co-ltures was effective even in
presence of estradiol. As shown in, Fig. 2c-d, inhibition of
VEGF resulted in a dose-dependent decrease of leptin levels
even in presence of estradiol whereas inhibition of leptin did
not result in any change of VEGF levels.
Co-Culture with Adipocytes Enhanced the Effects
of Estradiol on VEGF and Leptin Secretion
Co-culture per se increased the extracellular levels of VEGF
and leptin compared with the different cell types cultured
alone, Fig. 3a and c.
The release of VEGF and leptin from adipocytes was un-
affected by estradiol treatment, Fig. 3a and c. However, estra-
diol exposure significantly increased the extracellular levels of
VEGF and leptin from co-cultures to a much higher degree
than in MCF7 cells alone, Fig. 3a and c. In the case of leptin,
Fig. 1 VEGF correlated with
leptin and the ratio of
leptin:adiponectin in normal
human breast tissue.
Microdialysis was used for
sampling of extracellular VEGF,
leptin, and adiponectin in vivo in
normal breast tissue (extracellular
breast) and the abdominal
subcutaneous (s.c.) fat
(extracellular fat), in pre-and
postmenopausal women. Filled
circles represent women
investigated in the luteal phase of
the menstrual cycle and open
circles women investigated in the
follicular phase of the menstrual




extracellular leptin levels in
normal breast tissue, r = 0.6;
p < 0.0001; n = 43, but not in the
abdominal s.c. fat, r = 0.22;
p = 0.15; n = 41. b. VEGF did not
correlate with adiponectin in
normal breast tissue, r = 0.15;
p = 0.32; n = 43, or abdominal s.c.
fat tissue, r = 0.16; p = 0.31;
n = 41. c. There was a significant
positive correlation between
VEGF and the ratio of leptin to
adiponectin in normal breast
tissue, r = 0.4; p < 0.01; n = 43,
whereas no correlation was found
in abdominal s.c. fat tissue,
r = 0.23; p = 0.14; n = 41
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MCF7 cells cultured alone did not secrete any detectable
levels whereas in co-culture the levels were more than dou-
bled in the control group without hormone treatment com-
pared with adipocytes alone, and tripled after estradiol expo-
sure, Fig. 3c.
The pure anti-estrogen fulvestrant reversed the increase of
VEGF and leptin after estradiol exposure confirming the role
of the ER in the regulation of these proteins, Fig. 3b and d.
Adiponectin levels were unaltered in adipocytes compared
with co-cultures with or without estradiol treatment, Fig. 3e.
Dietary Addition of Flaxseed Decreased Leptin Levels
and Increased Adiponectin in Breast Tissue
Microdialysis was performed in ten premenopausal women in
two consecutive luteal phases of two menstrual cycles before
and after the addition of 25 g of ground flaxseed to the diet for
one month. No significant changes were detected in VEGF
levels in breast tissue or s.c. abdominal fat tissue. In normal
breast tissue the extracellular leptin levels decreased signifi-
cantly and adiponectin levels increased. The ratio leptin/
adiponectin was also significantly decreased in the breast.
No significant changes were observed in abdominal s.c. fat
tissue, Fig 4.
Discussion
In this study, we show that VEGF correlated significantly with
leptin and with the leptin:adiponectin ratio in normal human
breast tissue in situ. No correlations were found in abdominal
s.c. fat tissue. Co-culture of adipocytes and ER+ breast cancer
cells induced alterations per se with increased extracellular
levels of VEGF and leptin, and enhanced the effects of estra-
diol compared with either cell type cultured alone. In vitro,
VEGF had a regulatory effect on leptin and not vice versa. A
dietary addition of ground flaxseed decreased the in vivo ex-
tracellular breast levels of leptin and leptin:adiponectin ratio
whereas VEGF levels were unaltered.
The cellular composition of the breast provides a unique
microenvironment, contributing to several steps in the carci-
nogenic process [28]. This environment consists of different
cell types such as epithelial-, endothelial-, immune-, and stro-
ma cells and adipocytes. All of these cell types contribute to
biologically active secreted factors in the extracellular space.
This microenvironment is difficult to reproduce in in vitro
systems and commonly used techniques such as immunohis-
tochemistry of tissues may not reflect the extracellular com-
ponents. Microdialysis is a minimally invasive in vivo tech-
nique, which enables sampling of molecules from the extra-
cellular space of many organs. This sampling will, however,
not distinguish from which cell type the molecules originate.
The microdialysis technique has been adapted to sample bio-
active molecules present in situ in both normal and malignant
human breast tissue [15–17, 20, 29, 30]. By using microdial-
ysis, it has previously been shown that estradiol regulates
VEGF in normal human breast tissue in vivo and in breast
cancer models [16–19, 30, 31]. VEGF, being a potent angio-
genic factor, plays a key role in normal vascular growth,
alongside with its involvement in several pathological
Fig. 2 Inhibition of VEGF decreased leptin secretion in co-culture of
MCF7 and adipocytes. Co-culture of ER+ breast cancer cells, MCF7,
and freshly isolated human adipocytes, were exposed to; a. Anti-VEGF
antibody at 0.1 μg/ml and 1 μg/ml. Extracellular levels of leptin were
analyzed after 48 h. *, p < 0.05 and ****, p < 0.0001 compared with
controls, n = 5–6 in each group. b. Anti-leptin antibody at 0.1 μg/ml and
1 μg/ml. Extracellular levels of VEGF were analyzed after 48 h. n = 5–6
in each group. c. Anti-VEGF antibody at 0.1 μg/ml and 1 μg/ml in the
presence of estradiol (10−9 M). Extracellular levels of leptin were
analyzed after 48 h. ***, p < 0.001 and ****, p < 0.0001 compared with
controls, n = 5–6 in each group. d. Anti-leptin antibody at 0.1 μg/ml and
1 μg/ml in presence of estradiol (10−9 M). Extracellular levels of VEGF
were analyzed after 48 h. n = 5–6 in each group
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conditions such as cancer [9]. In addition to estrogen, VEGF
expression may also be regulated by several other factors in-
cluding hypoxia, cytokines, and growth factors [32, 33]. In
mouse mammary cancer cells, it has been shown that leptin
increased the expression of VEGF and its receptor VEGF-R2
[8] suggesting that VEGF may be regulated by leptin. Our
present data indeed support an interaction between leptin
and VEGF in normal human breast tissue in situ as extracel-
lular VEGF correlated significantly with leptin. None of these
correlations were detected in abdominal s.c. fat suggesting
tissue specific events in the breast. In our in vitro neutraliza-
tions experiments, inhibition of VEGF decreased extracellular
leptin levels in a dose-dependent fashion whereas inhibition of
leptin had no influence on VEGF levels. In contrast to previ-
ous animal studies, our data does not support the concept that
VEGF is under direct regulation of leptin in human tissues.
Although co-culture of two different cell types may not reflect
the complex environment in the breast tissue, it offers a more
physiologically relevant experimental model compared to sin-
gle cell cultures. In our present study, co-culture per se in-
creased the extracellular levels of leptin and VEGF compared
with the different cell types cultured alone, which imply the
importance of intercellular communication. Moreover, the ef-
fects of estradiol exposure seemed to be enhanced when the
cells were co-cultured compared to monoculture. Co-culture
of adipocytes and breast cancer cells resulted in a doubling of
Fig. 3 Co-culture with adipocytes enhanced the effects of estradiol on
leptin and VEGF secretion. A. MCF7 cells, freshly isolated human
adipocytes or co-culture of MCF7 and adipocytes, were cultured with
or without estradiol (10−9 M) for 48 h. Extracellular levels of VEGF were
measured in the conditioned medium with ELISA. ***, p < 0.001
and ****, p < 0.0001, n = 6. B. MCF7 cells alone or co-cultured with
adipocytes were treated with estradiol (10−9 M) or estradiol (10−9 M) and
fulvestrand (10−6 M) for 48 h. Extracellular levels of VEGF were
measured with ELISA in the conditioned medium. ***, p < 0.001 and
****, p < 0.0001, n = 6. C. MCF7 cells, adipocytes or co-culture of
MCF7 and adipocytes, were cultured with or without estradiol (10−9 M)
for 48 h. Extracellular levels of leptin were measured with ELISA in the
conditioned medium. ***, p < 0.001, n = 6. D. MCF7 cells alone or co-
cultured with adipocytes were treated with estradiol (10−9 M) or estradiol
(10−9 M) and fulvestrant (10−6 M) for 48 h. Extracellular levels of leptin
were measured with ELISA in the conditioned medium. *, p < 0.05 and
***, p < 0.001, n = 6. E. MCF7 cells, adipocytes or co-culture of MCF7
and adipocytes, were cultured with or without estradiol (10−9 M) for 48 h.
Extracellular levels of adiponctin were measured with ELISA in the
conditioned medium. n = 6 in each group
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the leptin levels compared to adipocytes cultured alone where-
as the levels were tripled in presence of estradiol. This high-
lights the importance of the cross talk between different cell-
types for the biological function of a tissue. As all
established so-called normal breast epithelial cell lines
do not express the ER, we chose to use ER positive
breast cancer cells to be able to elucidate the role of estrogen
in these regulations [26, 27].
Life style factors such as diet have been shown to attenuate
the risk of breast cancer in different populations [34, 35] and
previous studies have shown that a dietary addition of flaxseed
to premenopausal women tipped the breast microenvironment
into angiogenesis inhibition and anti-inflammatory conditions
[15, 21]. Here we show that flaxseed affected leptin and
adiponectin levels whereas VEGF levels were unaltered.
Adiponectin levels increased in eight out of ten women and
in two women the increase was nearly ten-fold. The duration
of the diet addition of flaxseed ranged between 26 and 33 days
depending on the individual differences in menstrual cycle
length. The ten-fold increase in the two women may reflect
an altered response to the diet rather than a longer duration of
the flaxseed addition as these women added flaxseed for 29
and 30 days respectively. Although our in vitro data suggested
a VEGF dependent alteration of leptin the diet modification
showed that leptin levels were affected even in absence of an
alteration of VEGF. This suggests that flaxseed may regulate
leptin and adiponectin by direct mechanisms or that indirectly
mechanisms other thanVEGFmay be involved. Alterations of
the microenvironment into a pro-tumorigenic state are key
events in the initiation, growth, and progression of cancers
including breast cancer. Autopsy studies have revealed that
up to 15 % of all women have in situ cancer in their breast
whereas only 1 % of women in the same age range are
diagnosed with breast cancer [36]. A pro-tumorigenic envi-
ronment may allow these in situ cancers to develop into clin-
ical cancer disease. Our present data suggest that the breast
microenvironment may be affected by relatively modest die-
tary modification and that flaxseed may induce an anti-
tumorigenic microenvironment.
In summary, this study shows that extracellular VEGF ex-
hibits a positive correlation with leptin in normal human breast
tissue in vivo. The in vitro cell culture experiments imply that
VEGF affects leptin expression and not vice versa. Co-culture
with ER+ breast cancer cells and adipocytes induced profound
changes of the extracellular environment per se and enhanced
the effects of estradiol. Dietary addition of flaxseed resulted in
decreased leptin and increased adiponectin levels in normal
human breast tissue. There is a need to develop safer and less
toxic breast cancer preventive strategies. Diet alterations could
be one preventive breast cancer measure and the regulation of
the breast microenvironment needs to be taken into account in
future mechanistic studies of such interventions.
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